AU2021381423A1 - Treatment of kras mutant cancers - Google Patents

Treatment of kras mutant cancers Download PDF

Info

Publication number
AU2021381423A1
AU2021381423A1 AU2021381423A AU2021381423A AU2021381423A1 AU 2021381423 A1 AU2021381423 A1 AU 2021381423A1 AU 2021381423 A AU2021381423 A AU 2021381423A AU 2021381423 A AU2021381423 A AU 2021381423A AU 2021381423 A1 AU2021381423 A1 AU 2021381423A1
Authority
AU
Australia
Prior art keywords
voruciclib
days
cancer
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021381423A
Other languages
English (en)
Other versions
AU2021381423A9 (en
Inventor
Daniel P. Gold
Sandra E. Wiley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of AU2021381423A1 publication Critical patent/AU2021381423A1/en
Publication of AU2021381423A9 publication Critical patent/AU2021381423A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021381423A 2020-11-19 2021-11-19 Treatment of kras mutant cancers Pending AU2021381423A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063115969P 2020-11-19 2020-11-19
US63/115,969 2020-11-19
US202163154652P 2021-02-26 2021-02-26
US63/154,652 2021-02-26
US202163158849P 2021-03-09 2021-03-09
US63/158,849 2021-03-09
US202163173361P 2021-04-10 2021-04-10
US63/173,361 2021-04-10
PCT/US2021/060151 WO2022109307A1 (en) 2020-11-19 2021-11-19 Treatment of kras mutant cancers

Publications (2)

Publication Number Publication Date
AU2021381423A1 true AU2021381423A1 (en) 2023-06-22
AU2021381423A9 AU2021381423A9 (en) 2024-02-08

Family

ID=81709695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021381423A Pending AU2021381423A1 (en) 2020-11-19 2021-11-19 Treatment of kras mutant cancers

Country Status (9)

Country Link
US (1) US20240016781A1 (https=)
EP (1) EP4247806A4 (https=)
JP (1) JP2024500288A (https=)
KR (1) KR20230148144A (https=)
AU (1) AU2021381423A1 (https=)
CA (1) CA3198938A1 (https=)
IL (1) IL302925A (https=)
MX (1) MX2023005806A (https=)
WO (1) WO2022109307A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
EP4376839A4 (en) * 2021-07-26 2025-10-15 Vincerx Pharma Inc SELECTIVE CDK9 INHIBITOR FOR THE TREATMENT OF RAS MUTANT CANCER
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
IL319991A (en) * 2022-10-03 2025-06-01 Prelude Therapeutics Inc Cancer treatment using combinations of SMARCA2 inhibitors and KRAS-targeted therapies
WO2024173833A1 (en) * 2023-02-16 2024-08-22 Mei Pharma, Inc. Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563596B2 (en) * 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
CN105530931B (zh) * 2013-07-12 2019-11-08 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
US20220175750A1 (en) * 2018-04-23 2022-06-09 The Regents Of The University Of California Sustained release formulation for local delivery of cdk9 inhibitors
WO2020046966A1 (en) * 2018-08-27 2020-03-05 Kura Oncology, Inc. Treatment of adenocarcinomas with mapk pathway inhibitors
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2020271908B2 (en) * 2019-04-11 2025-12-04 Mei Pharma, Inc. Voruciclib poly morphs and methods of making and using thereof
CA3148504A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
WO2022217133A1 (en) * 2021-04-10 2022-10-13 Mei Pharma, Inc. Voruciclib dosing regimens and methods of treatment including the same

Also Published As

Publication number Publication date
KR20230148144A (ko) 2023-10-24
WO2022109307A1 (en) 2022-05-27
US20240016781A1 (en) 2024-01-18
EP4247806A4 (en) 2024-11-13
IL302925A (en) 2023-07-01
JP2024500288A (ja) 2024-01-09
CA3198938A1 (en) 2022-05-27
EP4247806A1 (en) 2023-09-27
AU2021381423A9 (en) 2024-02-08
MX2023005806A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
US20240016781A1 (en) Treatment of kras mutant cancers
US12171744B2 (en) Pharmaceutical combinations for the treatment of cancer
JP2023116503A (ja) （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
UA125216C2 (uk) Комбінована терапія
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
BR112020022148A2 (pt) Métodos de tratamento de câncer
JP2026016402A (ja) 癌治療
EP3484477B1 (en) Treatment of cancer
US20240197680A1 (en) Voruciclib dosing regimens and methods of treatment including the same
CN117043159A (zh) Kras突变型癌症的治疗
JP2026505728A (ja) ６－（３－（（５－クロロ－２－メトキシピリジン）－３－スルホンアミド）－２，６－ジフルオロフェニル）－ｎ－メチルイミダゾ［１，５－ａ］ピラジン－１－カルボキサミドの結晶形態及びその使用方法
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
HK40103356A (zh) Kras突变型癌症的治疗
WO2024173833A1 (en) Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer
EP4473966A1 (en) Cancer treatment agent including malt1 inhibiting drug as active ingredient
US20240091226A1 (en) Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
HK40102219A (zh) 沃鲁西林给药方案和包含所述方案的治疗方法
EP4504202A1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
CN117580571A (zh) 沃鲁西林给药方案和包含所述方案的治疗方法
WO2021155185A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
NZ786330A (en) Pharmaceutical combinations for the treatment of cancer
HK1175125B (en) Combinations of a pi3k inhibitor and a mek inhibitor
HK1175125A1 (en) Combinations of a pi3k inhibitor and a mek inhibitor

Legal Events

Date Code Title Description
SREP Specification republished